157 related articles for article (PubMed ID: 12356805)
1. P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals.
Meaden ER; Hoggard PG; Newton P; Tjia JF; Aldam D; Cornforth D; Lloyd J; Williams I; Back DJ; Khoo SH
J Antimicrob Chemother; 2002 Oct; 50(4):583-8. PubMed ID: 12356805
[TBL] [Abstract][Full Text] [Related]
2. Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.
Ford J; Boffito M; Maitland D; Hill A; Back D; Khoo S; Nelson M; Moyle G; Gazzard B; Pozniak A
J Antimicrob Chemother; 2006 Nov; 58(5):1009-16. PubMed ID: 16984898
[TBL] [Abstract][Full Text] [Related]
3. Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients.
Ford J; Boffito M; Wildfire A; Hill A; Back D; Khoo S; Nelson M; Moyle G; Gazzard B; Pozniak A
Antimicrob Agents Chemother; 2004 Jul; 48(7):2388-93. PubMed ID: 15215085
[TBL] [Abstract][Full Text] [Related]
4. P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance?
Jones K; Bray PG; Khoo SH; Davey RA; Meaden ER; Ward SA; Back DJ
AIDS; 2001 Jul; 15(11):1353-8. PubMed ID: 11504956
[TBL] [Abstract][Full Text] [Related]
5. Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP.
Janneh O; Owen A; Chandler B; Hartkoorn RC; Hart CA; Bray PG; Ward SA; Back DJ; Khoo SH
AIDS; 2005 Dec; 19(18):2097-102. PubMed ID: 16284458
[TBL] [Abstract][Full Text] [Related]
6. Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression.
Ford J; Cornforth D; Hoggard PG; Cuthbertson Z; Meaden ER; Williams I; Johnson M; Daniels E; Hsyu P; Back DJ; Khoo SH
Antivir Ther; 2004 Feb; 9(1):77-84. PubMed ID: 15040539
[TBL] [Abstract][Full Text] [Related]
7. Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virus.
Khaliq Y; Gallicano K; Venance S; Kravcik S; Cameron DW
Clin Pharmacol Ther; 2000 Dec; 68(6):637-46. PubMed ID: 11180024
[TBL] [Abstract][Full Text] [Related]
8. Interactions of HIV protease inhibitors with ATP-dependent drug export proteins.
Gutmann H; Fricker G; Drewe J; Toeroek M; Miller DS
Mol Pharmacol; 1999 Aug; 56(2):383-9. PubMed ID: 10419558
[TBL] [Abstract][Full Text] [Related]
9. The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals.
Koks CH; Crommentuyn KM; Hoetelmans RM; Burger DM; Koopmans PP; Mathôt RA; Mulder JW; Meenhorst PL; Beijnen JH
Br J Clin Pharmacol; 2001 Jun; 51(6):631-5. PubMed ID: 11422025
[TBL] [Abstract][Full Text] [Related]
10. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults.
Ribera E; Lopez RM; Diaz M; Pou L; Ruiz L; Falcó V; Crespo M; Azuaje C; Ruiz I; Ocaña I; Clotet B; Pahissa A
Antimicrob Agents Chemother; 2004 Nov; 48(11):4256-62. PubMed ID: 15504850
[TBL] [Abstract][Full Text] [Related]
11. Effect of saquinavir/ritonavir on P-glycoprotein activity in healthy volunteers using digoxin as a probe.
Schmitt C; Kaeser B; Riek M; Bech N; Kreuzer C
Int J Clin Pharmacol Ther; 2010 Mar; 48(3):192-9. PubMed ID: 20197013
[TBL] [Abstract][Full Text] [Related]
12. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors.
Profit L; Eagling VA; Back DJ
AIDS; 1999 Sep; 13(13):1623-7. PubMed ID: 10509562
[TBL] [Abstract][Full Text] [Related]
13. Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line.
Perloff MD; Von Moltke LL; Marchand JE; Greenblatt DJ
J Pharm Sci; 2001 Nov; 90(11):1829-37. PubMed ID: 11745741
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs.
Ieiri I; Tsunemitsu S; Maeda K; Ando Y; Izumi N; Kimura M; Yamane N; Okuzono T; Morishita M; Kotani N; Kanda E; Deguchi M; Matsuguma K; Matsuki S; Hirota T; Irie S; Kusuhara H; Sugiyama Y
J Clin Pharmacol; 2013 Jun; 53(6):654-61. PubMed ID: 23381882
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
[TBL] [Abstract][Full Text] [Related]
16. Assessing safety and efficacy of directed P-glycoprotein inhibition to improve the pharmacokinetic properties of saquinavir coadministered with ritonavir.
Huisman MT; Smit JW; Wiltshire HR; Beijnen JH; Schinkel AH
J Pharmacol Exp Ther; 2003 Feb; 304(2):596-602. PubMed ID: 12538811
[TBL] [Abstract][Full Text] [Related]
17. Reducing the boosting dose of ritonavir does not affect saquinavir plasma concentrations in HIV-1-infected individuals.
van der Lugt J; Gorowara M; Avihingsanon A; Burger D; Ananworanich J; Sringam K; Kerr S; Wit F; Lange J; Ruxrungtham K
AIDS; 2009 Jun; 23(9):1176-9. PubMed ID: 19451794
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes.
Janneh O; Jones E; Chandler B; Owen A; Khoo SH
J Antimicrob Chemother; 2007 Nov; 60(5):987-93. PubMed ID: 17890284
[TBL] [Abstract][Full Text] [Related]
19. Darunavir/ritonavir and efavirenz exert differential effects on MRP1 transporter expression and function in healthy volunteers.
Lee LS; Soon GH; Shen P; Yong EL; Flexner C; Pham P
Antivir Ther; 2010; 15(2):275-9. PubMed ID: 20386083
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, safety and efficacy of saquinavir/ ritonavir 1,000/100 mg twice daily as HIV type-1 therapy and transmission prophylaxis in pregnancy.
von Hentig N; Nisius G; Lennemann T; Khaykin P; Stephan C; Babacan E; Staszewski S; Kurowski M; Harder S; Haberl A
Antivir Ther; 2008; 13(8):1039-46. PubMed ID: 19195329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
